

Stockholm 24 June 2019

## Sobi's divestment of SOBI003

**Sobi is realigning the focus of its research & development, and as a result intends to divest SOBI003.**

We are immensely proud of the SOBI003 programme and are enormously grateful for the support and dedication of the clinical investigational sites, research teams, collaborators, participant families and patient organisations.

We remain convinced that SOBI003 represents a potentially major step forward in the treatment of MPS IIIA. However, it is outside the area where we will be focusing in the future, and therefore we have taken the decision to divest the programme.

We are doing everything we can to find a good home for the SOBI003 programme, and will keep the study teams, participants and other stakeholders informed of progress.

We have taken the decision that the divestment should not influence the already ongoing Ph 1/2 studies (NCT03423186 and NCT03811028). Therefore, provided that the study discontinuation criteria outlined in the protocol have not been met, then we are committed to each enrolled patient in the ongoing phase 1/2 study (cohorts 1-3; N=3 in each cohort) receiving a total of two years of treatment. This also includes the initiation of cohort 3 should that be recommended by the safety review committee.